Patents by Inventor Souphalone Luangsay
Souphalone Luangsay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11898145Abstract: The present disclosure provides antisense oligonucleotides targeting Regulator of telomere elongation helicase 1 (RTEL1). The disclosure also provides, enhanced antisense oligonucleotides targeting RTEL1 for use in treating and/or preventing a hepatitis B virus (HBV) infection. Also disclosed are pharmaceutical compositions and their use.Type: GrantFiled: February 1, 2022Date of Patent: February 13, 2024Assignee: Hoffmann-La Roche Inc.Inventors: Erik Funder, Natascha Hruschka, Susanne Kammler, Erich Koller, Brian Leonard, Souphalone Luangsay, Susanne Mohr, Tobias Nilsson, Søren Ottosen, Lykke Pedersen, Søren V. Rasmussen, Steffen Schmidt, Sabine Sewing, Daniel Turley, Johanna Marie Walther
-
Publication number: 20230331837Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.Type: ApplicationFiled: October 7, 2022Publication date: October 19, 2023Applicant: HOFFMANN-LA ROCHE INC.Inventors: Lykke PEDERSEN, Hassan JAVANBAKHT, Malene JACKEROTT, Soren OTTOSEN, Souphalone LUANGSAY
-
Patent number: 11732262Abstract: The present invention relates to a FUBP1 inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of FUBP1 inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules, such as oligonucleotides including siRNA, shRNA and antisense oligonucleotides, which are complementary to FUBP1 and capable of reducing a FUBP1 mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment and/or prevention of a HBV infection.Type: GrantFiled: October 5, 2020Date of Patent: August 22, 2023Inventors: Souphalone Luangsay, Barbara Testoni, Fabien Zoulim, Soren Ottosen, Lykke Pedersen
-
Publication number: 20230257748Abstract: The present invention relates to an A1CF inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of A1CF inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules which are complementary to A1CF and capable of reducing the level of an A1CF mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment of a HBV infection.Type: ApplicationFiled: February 17, 2023Publication date: August 17, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Dennis JUL HANSEN, Souphalone LUANGSAY, Alan James MUELLER-BRECKENRIDGE, Lykke PEDERSEN, Johanna Marie POSE VICENTE
-
Publication number: 20230193263Abstract: The present invention relates to a SBDS inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of SBDS inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules which are complementary to SBDS and capable of reducing the level of a SBDS mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment of a HBV infection.Type: ApplicationFiled: June 21, 2022Publication date: June 22, 2023Inventors: Souphalone Luangsay, Alan James Mueller-Breckenridge, Lykke Pedersen, Johanna Marie Walther
-
Publication number: 20230183692Abstract: The present invention relates to a SEPT9 inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of SEPT9 inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules which are complementary to SEPT9 and capable of reducing the level of a SEPT9 mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment of a HBV infection.Type: ApplicationFiled: June 21, 2022Publication date: June 15, 2023Inventors: Lykke Pedersen, Souphalone Luangsay, Johanna Marie Walther, Alan James Mueller-Breckenridge
-
Publication number: 20230122751Abstract: The present invention relates to a COPS3 inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of COPS3 inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules which are complementary to COPS3 and capable of reducing the level of a COPS3 mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment of a HBV infection.Type: ApplicationFiled: June 21, 2022Publication date: April 20, 2023Inventors: Lykke Pedersen, Souphalone Luangsay, Johanna Marie Walther, Alan James Mueller-Breckenridge
-
Publication number: 20230120063Abstract: The present invention relates to a SARAF inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of SARAF inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules which are complementary to SARAF and capable of reducing the level of a SARAF mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment of a HBV infection.Type: ApplicationFiled: June 21, 2022Publication date: April 20, 2023Inventors: Lykke Pedersen, Souphalone Luangsay, Johanna Marie Walther, Alan James Mueller-Breckenridge
-
Publication number: 20230118138Abstract: The present invention relates to a SCAMP3 inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of SCAMP3 inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules which are complementary to SCAMP3 and capable of reducing the level of a SCAMP3 mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment of a HBV infection.Type: ApplicationFiled: June 21, 2022Publication date: April 20, 2023Inventors: Lykke Pedersen, Souphalone Luangsay, Johanna Marie Walther, Alan James Mueller-Breckenridge
-
Patent number: 11466081Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.Type: GrantFiled: August 21, 2020Date of Patent: October 11, 2022Assignee: HOFFMANN-LA ROCHE INC.Inventors: Lykke Pedersen, Hassan Javanbakht, Malene Jackerott, Søren Ottosen, Souphalone Luangsay
-
Publication number: 20220251556Abstract: Enhanced antisense oligonucleotides targeting Regulator of telomere elongation helicase 1 (RTEL1), leading to modulation of the expression of RTEL1 or modulation of RTEL1 activity are provided. This disclosure relates to the use of enhanced antisense oligonucleotides targeting RTEL1 for use in treating and/or preventing a hepatitis B virus (HBV) infection, in particular a chronic HBV infection. This disclosure further relates to the use of the enhanced antisense oligonucleotides targeting RTEL1 for destabilizing cccDNA, such as HBV cccDNA. A pharmaceutical composition and its use in the treatment and/or prevention of a HBV infection is also described.Type: ApplicationFiled: February 1, 2022Publication date: August 11, 2022Applicant: HOFFMANN-LA ROCHE INC.Inventors: Erik FUNDER, Natascha HRUSCHKA, Susanne KAMMLER, Erich KOLLER, Brian LEONARD, Souphalone LUANGSAY, Susanne MOHR, Tobias NILSSON, Søren OTTOSEN, Lykke PEDERSEN, Søren V. RASMUSSEN, Steffen SCHMIDT, Sabine SEWING, Daniel TURLEY, Johanna Marie WALTHER
-
Publication number: 20220031730Abstract: The present invention relates to enhanced antisense oligonucleotides that are complementary to the Far Upstream Element-Binding Protein 1 (FUBP1) and are capable of reducing a FUBP1 target nucleic acid, such as FUBP1 mRNA. The invention relates to enhanced antisense oligonucleotides targeting FUBP1 or conjugates thereof for use in treating and/or preventing a hepatitis B virus (HBV) infection, in particular a chronic HBV infection. The invention in particular relates to the use of the enhanced antisense oligonucleotides targeting FUBP1 or conjugates thereof for destabilizing cccDNA, such as HBV cccDNA. The invention further relates to enhanced antisense oligonucleotides targeting FUBP1 or conjugates thereof for use in treating cancer. A pharmaceutical composition and its use in the treatment and/or prevention of an HBV infection, or its use in the treatment of cancer is also disclosed.Type: ApplicationFiled: June 25, 2021Publication date: February 3, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Sabine SEWING, Søren OTTOSEN, Jacob RAVN, Lykke PEDERSEN, Souphalone LUANGSAY, Erich KOLLER, Johanna Marie WALTHER, Helene Maria GYLLING, Natascha HRUSCHKA, Susanne MOHR, Valentina D'ARIENZO
-
Publication number: 20210147535Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.Type: ApplicationFiled: August 21, 2020Publication date: May 20, 2021Inventors: Lykke PEDERSEN, Hassan JAVANBAKHT, Malene JACKEROTT, Søren OTTOSEN, Souphalone LUANGSAY
-
Publication number: 20210024934Abstract: The present invention relates to a FUBP1 inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of FUBP1 inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules, such as oligonucleotides including siRNA, shRNA and antisense oligonucleotides, which are complementary to FUBP1 and capable of reducing a FUBP1 mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment and/or prevention of a HBV infection.Type: ApplicationFiled: October 5, 2020Publication date: January 28, 2021Inventors: Souphalone LUANGSAY, Barbara TESTONI, Fabien ZOULIM, Soren OTTOSEN, Lykke PEDERSEN
-
Patent number: 10829555Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.Type: GrantFiled: April 2, 2020Date of Patent: November 10, 2020Assignee: Hoffman-La Roche Inc.Inventors: Lykke Pedersen, Hassan Javanbakht, Malene Jackerott, Søren Ottosen, Souphalone Luangsay
-
Patent number: 10745480Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.Type: GrantFiled: October 25, 2019Date of Patent: August 18, 2020Assignee: Hoffmann-La Roche, Inc.Inventors: Lykke Pedersen, Hassan Javanbakht, Malene Jackerott, Søren Ottosen, Souphalone Luangsay
-
Publication number: 20200247884Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.Type: ApplicationFiled: April 2, 2020Publication date: August 6, 2020Inventors: Lykke PEDERSEN, Hassan JAVANBAKHT, Malene JACKEROTT, Søren OTTOSEN, Souphalone LUANGSAY
-
Publication number: 20200048344Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.Type: ApplicationFiled: October 25, 2019Publication date: February 13, 2020Inventors: Lykke Pedersen, Hassan Javanbakht, Malene Jackerott, Søren Ottosen, Souphalone Luangsay
-
Publication number: 20170283496Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.Type: ApplicationFiled: March 14, 2017Publication date: October 5, 2017Inventors: Lykke Pedersen, Hassan Javanbakht, Malene Jackerott, Søren Ottosen, Souphalone Luangsay